Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents [Hematologic Malignancy]

Conclusion
Lenalidomide yields sustained RBC-TI in 26.9% of RBC transfusion–dependent patients with lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was associated with improved HRQoL. Treatment-emergent adverse event data were consistent with the known safety profile of lenalidomide.

Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Santini, Almeida, Giagounidis, Gropper, Jonasova, Vey, Mufti, Buckstein, Mittelman, Platzbecker, Shpilberg, Ram, del Canizo, Gattermann, Ozawa, Risueno, MacBeth, Zhong, Seguy, Hoenekopp, Beach, Fenaux Tags: Chemotherapy Hematologic Malignancy Source Type: research